ChemoCentryx has initiatied Phase I clinical trials of CCX168, a novel orally administered small molecule designed to treat autoimmune diseases.
According to the company CCX168 is a highly potent and very selective compound that specifically targets the C5a receptor (C5aR), an important part of the inflammatory response associated with autoimmune diseases such as systemic lupus erythematosus, certain types of vasculitis, age-related macular degeneration and rheumatoid arthritis.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
ChemoCentryx president and CEO Thomas J Schall said that the company had demonstrated the ability to develop a compound targeting C5aR, which has proved to be an enormous challenge for the pharmaceutical industry.
“As a result, we bring to clinical development a C5aR antagonist unlike any other compound that has been developed to date,” Schall said.
The initiation of this Phase I trial triggered a $10m milestone payment from GlaxoSmithKline.

US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData